Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
IPO Year: 2017
Exchange: NASDAQ
Website: apellis.com
Recent Analyst Ratings for Apellis Pharmaceuticals Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $36.00 | Buy → Neutral | Goldman |
| 11/21/2024 | $31.00 | Equal-Weight | Morgan Stanley |
| 10/25/2024 | $25.00 | Sector Perform | RBC Capital Mkts |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/16/2024 | Outperform | William Blair | |
| 5/31/2024 | $46.00 | Neutral | Piper Sandler |
| 2/5/2024 | $68.00 → $80.00 | Hold → Buy | Jefferies |
| 12/14/2023 | Overweight → Equal Weight | Wells Fargo | |
| 11/9/2023 | $74.00 | Buy | Goldman |
| 11/2/2023 | $42.00 | Neutral | Mizuho |
Apellis Pharmaceuticals Inc. Press Releases
Fastest customizable press release news feed in the world
Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacoplan) full year 2024 net product revenue of $98.1 million Submitted a supplemental new drug application (sNDA) for approval of EMPAVELI for C3G and primary IC-MPGN; U.S. launch anticipated in 2H 2025, if approved On track to initiate two Phase 3 trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $411.3 million as of December 31, 2024; projected revenues and cash expected to be sufficient to fund operations to p
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. The live conference webcast will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments. "C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life," said Lydia Abad-Franch, M.D., head of R&D and medical affairs and chief medi
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that the company approved the grant of equity awards to three new employees with a grant date of February 3, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received 7,805 restricted stock units (RSUs). Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an intact fovea and when central vision is threatened by GA lesion growth. SYFOVRE is the first and only approved treatment for GA in Australia. "The approval of SYFOVRE marks a significant milestone for GA patients across Australia. For the first time, Australians with GA will have a treatment to slow the progression of this irreversible form of vision loss,
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net product revenues, including $23 million in 4Q 2024 Expects submission of EMPAVELI sNDA for C3G and primary IC-MPGN in early 2025; U.S. launch anticipated in 2H 2025, if approvedPlans initiation of Phase 3 studies of pegcetacoplan in two additional nephrology indications in 2H 2025Adam Townsend, chief operating officer, to depart Apellis in February; David Acheson named executive vice president of commercialMaintained strong financial position with year-end cash of approximately $410 million; proj
Apellis Announces Keli Walbert to Join the Board of Directors
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. "We are delighted to welcome Keli to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Keli has a proven track record of successfully bringing novel medicines to patients as well as a respected reputation among industry leaders for her strategic thinking and innovation. Her deep commercial expertise will be invaluable as we c
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 2, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received 4,135 restricted stock units (RSUs). Each RSU will vest as to 25% of the shares underlying
Apellis Pharmaceuticals Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Apellis Pharmaceuticals downgraded by Goldman with a new price target
Goldman downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $36.00
Morgan Stanley initiated coverage on Apellis Pharmaceuticals with a new price target
Morgan Stanley initiated coverage of Apellis Pharmaceuticals with a rating of Equal-Weight and set a new price target of $31.00
RBC Capital Mkts initiated coverage on Apellis Pharmaceuticals with a new price target
RBC Capital Mkts initiated coverage of Apellis Pharmaceuticals with a rating of Sector Perform and set a new price target of $25.00
Scotiabank initiated coverage on Apellis Pharmaceuticals
Scotiabank initiated coverage of Apellis Pharmaceuticals with a rating of Sector Outperform
William Blair initiated coverage on Apellis Pharmaceuticals
William Blair initiated coverage of Apellis Pharmaceuticals with a rating of Outperform
Piper Sandler initiated coverage on Apellis Pharmaceuticals with a new price target
Piper Sandler initiated coverage of Apellis Pharmaceuticals with a rating of Neutral and set a new price target of $46.00
Apellis Pharmaceuticals upgraded by Jefferies with a new price target
Jefferies upgraded Apellis Pharmaceuticals from Hold to Buy and set a new price target of $80.00 from $68.00 previously
Apellis Pharmaceuticals downgraded by Wells Fargo
Wells Fargo downgraded Apellis Pharmaceuticals from Overweight to Equal Weight
Goldman initiated coverage on Apellis Pharmaceuticals with a new price target
Goldman initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $74.00
Mizuho initiated coverage on Apellis Pharmaceuticals with a new price target
Mizuho initiated coverage of Apellis Pharmaceuticals with a rating of Neutral and set a new price target of $42.00
Apellis Pharmaceuticals Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
VP/Chief Accounting Officer Chopas James George sold $4,543 worth of shares (183 units at $24.82), decreasing direct ownership by 0.38% to 47,955 units (SEC Form 4)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
General Counsel Watson David O. sold $139,789 worth of shares (5,569 units at $25.10), gifted 6,667 shares and received a gift of 6,667 shares, decreasing direct ownership by 4% to 138,730 units (SEC Form 4)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
Chief Business & Strat Officer Delong Mark Jeffrey sold $10,360 worth of shares (363 units at $28.54), decreasing direct ownership by 0.43% to 83,945 units (SEC Form 4)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
General Counsel Watson David O. sold $20,519 worth of shares (695 units at $29.52), decreasing direct ownership by 0.48% to 144,299 units (SEC Form 4)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
Chief Commercial Officer Townsend Adam J. sold $20,519 worth of shares (695 units at $29.52), decreasing direct ownership by 0.82% to 84,050 units (SEC Form 4)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
Chief Financial Officer Sullivan Timothy Eugene sold $16,120 worth of shares (546 units at $29.52), decreasing direct ownership by 0.42% to 128,665 units (SEC Form 4)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
Chief Technical Officer Nicholson Nur sold $24,357 worth of shares (825 units at $29.52), decreasing direct ownership by 0.98% to 83,664 units (SEC Form 4)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
Chief People Officer Lewis Karen sold $10,747 worth of shares (364 units at $29.52), decreasing direct ownership by 0.52% to 70,251 units (SEC Form 4)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
Chief Development Officer Eisele Jeffrey sold $8,208 worth of shares (278 units at $29.52), decreasing direct ownership by 0.50% to 55,312 units (SEC Form 4)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
Chief Scientific Officer Deschatelets Pascal sold $24,386 worth of shares (826 units at $29.52), decreasing direct ownership by 0.07% to 1,147,716 units (SEC Form 4)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
Apellis Pharmaceuticals Inc. SEC Filings
SEC Form S-8 filed by Apellis Pharmaceuticals Inc.
S-8 - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
SEC Form 10-K filed by Apellis Pharmaceuticals Inc.
10-K - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Apellis Pharmaceuticals Inc.
SCHEDULE 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form SCHEDULE 13G filed by Apellis Pharmaceuticals Inc.
SCHEDULE 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form 144 filed by Apellis Pharmaceuticals Inc.
144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form 144 filed by Apellis Pharmaceuticals Inc.
144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form 144 filed by Apellis Pharmaceuticals Inc.
144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form 144 filed by Apellis Pharmaceuticals Inc.
144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
Apellis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
8-K - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
SEC Form 10-Q filed by Apellis Pharmaceuticals Inc.
10-Q - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
Apellis Pharmaceuticals Inc. FDA approvals
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC
Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity
Apellis Pharmaceuticals Inc. Leadership Updates
Live Leadership Updates
Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted
Apellis Announces Keli Walbert to Join the Board of Directors
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. "We are delighted to welcome Keli to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Keli has a proven track record of successfully bringing novel medicines to patients as well as a respected reputation among industry leaders for her strategic thinking and innovation. Her deep commercial expertise will be invaluable as we c
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18. "Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Retina Specialists (ASRS), so we are delighted to welcome him to the Apellis team," said Caroline Baumal, M.D., Chief Medical Officer, Apellis. "Phil has extensive expertise in retina research and patient care, which will be invaluable as we continue to bring SYFOVRE to patients with GA and advance our retina pipeline." "It is an honor to jo
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces Federico Grossi, M.D., Ph.D., who plans to remain at Apellis until February 28, 2023 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy (GA). "Caroline is a world-renowned retina specialist who has been at the forefront of retina research and patient care for over 25 years, and we are thrilled to welcome her to Apellis," said Cedric Francois, M.
Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board
Cognito Therapeutics, a Phase 3-ready disease-modifying digital therapeutics company, today announced the appointment of Gerald Chan, ScD. as Chairman of the Board. Cognito is a pioneer in using neuromodulation to engage novel targets of neuronal pathophysiology to achieve disease modification in neurodegenerative diseases. Dr. Chan is the co-founder of Morningside, a privately held venture capital and private equity firm. Since inception, Morningside has focused on the development and commercialization of novel scientific discoveries in both the life sciences and technology sectors. "The use of non-pharmacological interventions to treat neurocognitive decline represents a fundamental shif
Apellis Pharmaceuticals Inc. Financials
Live finance-specific insights
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacoplan) full year 2024 net product revenue of $98.1 million Submitted a supplemental new drug application (sNDA) for approval of EMPAVELI for C3G and primary IC-MPGN; U.S. launch anticipated in 2H 2025, if approved On track to initiate two Phase 3 trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $411.3 million as of December 31, 2024; projected revenues and cash expected to be sufficient to fund operations to p
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue of $152.0 million Increase in demand offset by higher gross-to-net adjustments in the quarter Following FDA feedback, on track to file an sNDA seeking approval of pegcetacoplan for C3G / primary IC-MPGN in early 2025 based on positive 6-month Phase 3 VALIANT results Cash and cash equivalents of $396.9 million as of September 30, 2024; projected revenues and cash expected to be sufficient to fund operations to positive cash flow Management to host conference call today at 8:30 a.m. ET
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2024 financial results on Tuesday, November 5, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study populationPositive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneysDemonstrated favorable safety, consistent with established profileCompanies plan to submit data for regulatory approval in the US and EU Apellis to host a conference call today at 8:00 a.m. ET WALTHAM, Mass. and STOCKHOLM, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and Sobi® (STO: SOBI) today announced positive topline results from the Phase 3 VALIANT study investi
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
Generated $199.7 million in 2Q 2024 revenues, including $179.1 million in U.S. net product sales $154.6 million for SYFOVRE® (pegcetacoplan injection) $24.5 million for EMPAVELI® (pegcetacoplan) Initiated a re-examination of the marketing authorization application of SYFOVRE with the European Medicines Agency (EMA); expect a final decision in 4Q 2024 Plan to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in August 2024Cash and cash equivalents of $360.1 million as of June 30, 2024; projected revenues and cash expected to be sufficient to fund operations to positive cash flow Management to host conference call today at 8:30 a.m. ET WALTHAM, Mass., Aug. 01, 2024 (
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA no later than July 2024On track to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in mid-2024Cash and cash equivalents of $325.9 million as of March 31, 2024; projected revenues and cash expected to be sufficient to fund operations for foreseeable futureManagement to host conference call today at 8:30 a.m. ET WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), today announced its f
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines cour
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan)Strong SYFOVRE launch, with more than 160,000 total doses (commercial and samples) distributed in 2023 Topline data from Phase 3 VALIANT study of systemic pegcetacoplan in C3G and IC-MPGN expected in mid-2024Cash and cash equivalents of $351 million as of December 31, 2023 WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), today announced its fourth quarter and full year 2023 financial results and business highlights. "I am extremely proud of our team, their accomplishments and resilience
Apellis Pharmaceuticals Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.
SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.
SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)